Safer use can be ensured by keeping your doctor informed on a regular basis and being aware of any unexpected symptoms
Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis, Cureus (2023) The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists, Diabetes, Obesity, and Metabolism (2020) What is the incidence of pancreatitis associated with Zepbound (tirzepatide)?, Eli Lilly website (2024) Constipation and impaction, Harvard Health (2023) Pancreatitis, Johns Hopkins Medicine (2025) Gallstones and gallbladder disease, Mount Sinai Zepbound label, Food and Drug Administration (2025) Gingers nutritional implication on gastrointestinal health, Clinical Nutrition Open Science (2025) Review article: The physiologic effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders, Alimentary Pharmacology and Therapeutics (2018) Efficacy and safety of peppermint oil in a randomized double-blind trial of patients with irritable bowel syndrome, Gastroenterology (2020) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Specific mechanisms: how tirzepatide protects erectile function Understanding the specific biological mechanisms helps explain why tirzepatide is protective rather than harmful for erectile function
What is generally okay
You may need to delay your next dose increase or temporarily reduce your dose
